Azenta’s wholly‑owned subsidiary, Azenta UK Ltd, closed its acquisition of UK Biocentre Limited for a total consideration of £20.5 million, net of cash, with an additional contingent payment of up to £1.8 million tied to milestone achievement.
UK Biocentre generated £15.3 million in revenue during the twelve months ending September 30 2025. The transaction is expected to be dilutive to Azenta’s 2026 adjusted EBITDA margin by roughly 35 basis points, but it is projected to be accretive to organic revenue growth and margin expansion in 2027‑2028.
Strategically, the deal positions Azenta as a European‑wide operational hub, complementing its existing biorepository in Griesheim, Germany, and enhances its end‑to‑end sample‑management platform. The acquisition will support the deployment of the 16‑million‑sample BioArc Ultra system later this year and expands Azenta’s footprint in a consolidating life‑sciences market, reinforcing its focus on high‑margin sample‑management solutions.
UK Biocentre will be integrated under the Azenta brand while continuing to operate under its current name. Azenta will host a conference call on March 10 2026 to discuss integration plans and expected synergies with investors and analysts.
The acquisition is expected to accelerate Azenta’s growth trajectory in the UK and broader Europe, providing a stronger platform for pharmaceutical, biotechnology, academic, and public‑health customers. By adding UK Biocentre’s established sample‑management, storage, and high‑throughput processing services, Azenta strengthens its competitive position and sets the stage for long‑term revenue and margin growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.